ArticleThe World Allergy Organization journal2020
Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results.
Article in The World Allergy Organization journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- The Economic Burden of Chronic Urticaria in Portugal: A Patient-Reported Cost-of-Illness Study.Dermatology and therapy · 2026Article
- Unmet Needs in Treatment Escalation for Chronic Spontaneous Urticaria: Findings From the CURE Registry.Allergy · 2026Article
- Knowledge among primary care physicians on urticaria treatment: Impact of educational interventions.The journal of allergy and clinical immunology. Global · 2026Article
- A Concordance Study between Patient Acceptable Symptom State (PASS) and Disease Activity in Chronic Spontaneous Urticaria.Dermatology practical & conceptual · 2026Article
- Identifying and Evaluating Patient-Centered Mobile and Web Apps for Patients With Chronic Spontaneous Urticaria: Systematic Search and Content Analysis.JMIR mHealth and uHealth · 2026Article
- An Assessment of Melatonin Levels in the Saliva of Patients with Chronic Urticaria in Comparison with Their Sleep Quality and Dermatologic Quality of Life.Clinics and practice · 2026Article
- Advancements and challenges in the management of chronic inducible urticaria.Frontiers in immunology · 2026Review
- Urticaria Voices: Real-World Treatment Patterns and Outcomes in Chronic Spontaneous Urticaria.Dermatology and therapy · 2025Article
- Assessing Preferences of Patients with Chronic Spontaneous Urticaria for Injectable Treatment Profiles.The patient · 2025Article
- Urticaria Voices: Real-World Experience of Patients Living with Chronic Spontaneous Urticaria.Dermatology and therapy · 2025Article
- Chronic inducible urticaria - having more than one is common and clinically relevant.Frontiers in immunology · 2025Article
- New insights into chronic inducible urticaria.Current allergy and asthma reports · 2024Review
- Disease burden and predictors associated with non-response to antihistamine-based therapy in chronic spontaneous urticaria.The World Allergy Organization journal · 2023Article
- SALIVARY MELATONIN VALUES SIGNIFICANTLY CORRELATE WITH REDUCED QUALITY OF LIFE IN CHRONIC SPONTANEOUS URTICARIA PATIENTS: A PILOT STUDY.Acta clinica Croatica · 2023Article
- Chronic Spontaneous Urticaria: How to Measure It and the Need to Define Treatment Success.Dermatology and therapy · 2023Review
- Urticaria.Nature reviews. Disease primers · 2022Review
- The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologicsEuropean journal of dermatology : EJD · 2022Article
- Integrated bioinformatics to identify potential key biomarkers for COVID-19-related chronic urticaria.Frontiers in immunology · 2022Article
- Comorbidities of Chronic Urticaria: A glimpse into a complex relationship.Frontiers in allergy · 2022Review
- Urticaria in Pregnancy and Lactation.Frontiers in allergy · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA Worldwide Antihistamine-Refractory Chronic Urticaria (CU) patient Evaluation (AWARE) is a non-interventional, multicenter study including patients from Europe, Central and Latin America, Asia-Pacific, and the Middle East. AWARE describes real-world evidence for CU, including clinical characteristics, treatment patterns and the impact on quality of life.
methodsOver the 2-year study, therapy changes, angioedema occurrence, and patient-reported outcomes (PROs) were recorded over 9 visits, including dermatology life quality index (DLQI) and 7-day urticaria activity score (UAS7). Data were stratified into subgroups: chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), or CSU + CIndU.
resultsOut of 4838 patients analyzed, 9.9% were receiving no treatment for their CU symptoms at baseline, and 20.4% were receiving first-line non-sedating H
conclusionCU patients are undertreated at baseline; after entering the AWARE study, more patients received appropriate treatment. However, over two thirds are not escalated to third-line treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.